Newsletter | June 22, 2025

06.22.25 -- Implications Of California's AB 824 Patent Settlement Regulation

FEATURED ARTICLE

Implications Of California's AB 824 Patent Settlement Regulation

California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB 824 presumes, for example, that "reverse payment" agreements are illegal.

Milestone Payments: Potential Trouble In The Last Mile?

Biotech Angel Investing With Yaniv Sneor

INDUSTRY INSIGHTS

Cost And Scalability Key Drivers Of Expanded Gene Therapy Access

Optimizing Upstream And Downstream Intensification

How Do Site Payments Impact Clinical Trial Sustainability?

Reducing ADC Timelines With Integrated Development And Manufacturing

Navigating The Complex World Of First-In-Human Oncology Trials

Data Analytics' Role In Driving Commercialization And Clinical Success

What Treatment Options Do You Have For Me?

Genentech To Build $700M Fill-Finish Facility In Holly Springs

5 Questions On Exploring Healthcare Decision-Maker Sentiments

Why Taxes Jeopardize Clinical Trial Access And How You Can Help

Navigating The Complexities Of Publication Planning

The Benefits Of U.S. Biotechs Conducting Clinical Trials In Australia

Unlocking Potential: A Deep Dive Into AAV Development And Manufacturing

Accelerating Clinical Data Review With Traceable Workflows

It's Time To Use It Europe's Platform For Driving More Flexible Clinical Trials

Customized Release Through Dispersed Dosage Formats

What Is Direct-To-Patient Clinical Trial Recruitment?

Rare Disease R&D: Continued Growth Amid Challenges